Emily S. Ruiz MD, MPH
Associate Physician, Mohs and Dermatologic Surgery Center, Brigham and Women’s Faulkner Hospital; Assistant Professor, Dermatology, Harvard Medical School; Director, High-Risk Skin Cancer Clinic, Dana Farber/Brigham and Women’s Hospital, Boston, MassachusettsEmily Ruiz, MD, MPH, is an Associate Physician at the Mohs and Dermatologic Surgery Center at Brigham and Women’s Faulkner Hospital, Assistant Professor in Dermatology at Harvard Medical School and Director of the High-Risk Skin Cancer Clinic at Dana Farber/Brigham and Women’s Hospital.
Dr. Ruiz received her undergraduate degree from Duke University, medical degree from New York University School of Medicine, and Master of Public Health Degree from Harvard School of Public Health. She completed an internship in internal medicine at New York University School of Medicine, dermatology residency at Albert Einstein College of Medicine, and fellowship in Micrographic Surgery and Dermatologic Oncology at Brigham and Women’s Hospital.
Dr. Ruiz’s career is dedicated to patient care, clinical innovation, education, and skin cancer research. She spends 60% of her time in outpatient clinical activities and the remainder of time is devoted to clinical research and education. The majority of her clinical time is spent performing Mohs micrographic surgery and one clinic a week is at Dana-Farber Cancer Institute. This clinic is a referral site for aggressive non-melanoma skin cancers and provides skin cancer surveillance to high-risk patients, including transplant patients and individuals with a history of a high-risk skin cancer. It is also is a site for two clinical trial for a programmed cell death protein 1 (PD-1) inhibitor for patients with locally advanced and metastatic cutaneous squamous cell carcinoma and basal cell carcinoma.
Dr. Ruiz’s primary research interest is cost analyses of skin cancer care. She received a Career Development Award from the Dermatology Foundation and a Cutting-Edge Research Grant from the American Society for Dermatologic Surgery for my study entitled “Skin Cancer Equity and Expenditure Analysis.” Additionally, she is interested in treatment and outcomes of non-melanoma skin cancer. She is also the principal investigator on a clinical study at Brigham and Women’s Hospital that evaluates intraoperative immunohistochemistry staining with p40 antibody during Mohs micrographic surgery for poorly-differentiated cutaneous squamous cell carcinoma. Additionally, she is evaluating outcomes of adnexal carcinomas in a retrospective cohort.
She lives in Boston, Massachusetts, with her husband and her daughters.
Disclosures
Dr. Ruiz reports the following:Advisory Board or Panel: Leo Pharma, Checkpoint Therapeutics - Active Consultant Sanofi - Active , Pellepharm Inc, and Jounce.